Severe mpox has been observed in people with advanced human immunodeficiency virus (HIV). We describe clinical outcomes of 13 patients with advanced HIV (CD4 <200 cells/μL), severe mpox, and multiorgan involvement. Despite extended tecovirimat courses and additional agents, including vaccinia immune globulin, cidofovir, and brincidofovir, this group experienced prolonged hospitalizations and high mortality.
Keywords: HIV/AIDS; immunocompromise; mortality; mpox treatment; tecovirimat.
© The Author(s) 2024. Published by Oxford University Press on behalf of Infectious Diseases Society of America.